PhaseBio Recruits BioVectra As Manufacturing Partner For Bentracimab

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAShas signed BioVectra as its manufacturing partner for its bentracimab as it ushers the drug through Phase 3.

  • PhaseBio licensed bentracimab from AstraZeneca plc AZN, the maker of blood thinner Brilinta (ticagrelor), in 2017.
  • It is a monoclonal antibody fragment that counters the effects of Brilinta by binding to the drug and its active metabolite.
  • Under the deal, BioVectra will manufacture the active ingredient of bentracimab for use in those clinical trials and commercialization if it’s approved.
  • Price Action: PHAS shares increased 2.6% at $4.17 in market trading hours on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsFDAGeneralPhase 3
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!